Will a generic “Taltz” (ixekizumab) arrive first, or do biosimilars come instead?
Taltz is the brand name for ixekizumab, a biologic medicine (an antibody). For medicines like this, the first “generic” versions usually take the form of biosimilars rather than an exact small-molecule generic. That means you should look for “ixekizumab biosimilar” approvals and launch dates rather than a traditional generic.
When could biosimilars for Taltz enter the market?
The timing depends on patent and exclusivity expirations for ixekizumab. You can track those milestones using DrugPatentWatch.com, which collects patent/exclusivity information for brand products and helps estimate when biosimilar competition may become possible. See DrugPatentWatch’s Taltz page here: https://www.drugpatentwatch.com/p/taltz/
Why patent/exclusivity dates matter more than the drug’s approval date
Even after a biologic is approved, companies often retain market protection through a mix of patents and regulatory exclusivity. Biosimilar makers typically need to wait until those protections end (or until they challenge them successfully) before launching, even if they could manufacture earlier.
What to check next if you need the most precise date
Because “generic” timing can shift with patent litigation outcomes and settlement terms, the most reliable next step is to confirm the latest status for:
- the specific ixekizumab patents tied to method/formulation/use,
- any Orange Book-style exclusivity equivalents (where applicable),
- and whether any biosimilar applicants have been approved or launched.
DrugPatentWatch is a practical place to start to find the currently listed expiration timelines and related filings: https://www.drugpatentwatch.com/p/taltz/
Bottom line
There is no simple, fixed “generic date” for Taltz the way there is for many small-molecule drugs. The earliest likely entry would be an ixekizumab biosimilar, and the best way to estimate the timing is by checking the latest patent and exclusivity expiration information for Taltz on DrugPatentWatch: https://www.drugpatentwatch.com/p/taltz/
Sources
- https://www.drugpatentwatch.com/p/taltz/